Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dengue Vaccine Formulation 17
Dengue Vaccine · 1 trial · 1 indication
Number of solicited general symptoms within the 21-day follow-up after dengue dose 1 (total vaccinated cohort).
| Arm | Type | Description |
|---|---|---|
| Dengue and Japanese Encephalitis vaccine | EXPERIMENTAL | 1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5. |
| Name | Type | Description |
|---|---|---|
| Dengue Vaccine Formulation 17 | BIOLOGICAL | Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60. |
| Licensed Japanese Encephalitis (JE) Vaccine | BIOLOGICAL | Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months. |
Inclusion Criteria: * A male or female child six to nine years of age (greater than or equal to 6 years of age and less than 10 years of age) at the time of the first vaccination. * Free of obvious health problems as established by medical history and physical examination before entering into the s...
The Dengue Vaccine is an investigational vaccine being developed by GSK plc for the prevention of dengue fever, an infectious disease. It is a vaccine candidate that has been studied in early-stage clinical research. It is not yet an approved product.
The Dengue Vaccine is being developed for dengue fever, an infectious disease caused by dengue virus. The candidate is a vaccine intended to prevent the disease. It remains investigational and has only been evaluated in a Phase 1 clinical trial.
The Dengue Vaccine is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this dengue vaccine candidate.
The Dengue Vaccine is in Phase 1 development. It is investigational and has not been approved. One Phase 1 trial has been completed, and no trials are currently active.
The Dengue Vaccine has been studied in one completed Phase 1 trial, NCT00384670, titled A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children. The trial enrolled 7 participants in Thailand and has completed.
Yes. Dengue Vaccine Formulation 17 is another name for the Dengue Vaccine developed by GSK plc. Both names refer to the same investigational vaccine candidate for dengue fever.